Boucher and Muir

Boucher and Muir is a pharmaceutical company focusing on the delivery of niche, established medical products, primarily for healthcare providers and patients in Australia and the South Pacific regions. Boucher and Muir operates as a subsidiary of ADVANZ PHARMA and is dedicated to enhancing access to established pharmaceutical products. Founded in 1957 and headquartered in Sydney, Australia, the company has undergone strategic shifts to align its operations with market needs. In July 2015, ADVANZ PHARMA acquired Boucher and Muir, streamlining its offerings within the healthcare sector.

Boucher and Muir specializes in delivering established pharmaceutical products, targeting healthcare providers and patients across Australia, New Zealand, and the South Pacific Islands. Their product portfolio includes medicines under the Amdipharm and Mercury brands, focusing on revitalizing established medicines to ensure high-quality options for patients. Their business model emphasizes partnerships with healthcare providers to enhance the patient experience through accessible treatments. In the most recent fiscal year of 2006, Boucher and Muir reported a revenue of USD 10.

72 mn and an EBITDA of USD 457,168. 6, reflecting the company’s operational scale and market engagement strategies. Boucher and Muir plans to utilize recent funding from its acquisition by ADVANZ PHARMA to expand its product portfolio and enhance market reach. The company is focusing on launching new products aimed at addressing unmet medical needs.

Additionally, it is targeting expansion into the New Zealand market by 2025, leveraging its established pharmaceutical lines to cater to healthcare providers and patients effectively.